C. Lemanski
French Institute of Health and Medical Research
CancerInternal medicineRadiologySurgeryOncologyRandomized controlled trialStage (cooking)Prospective cohort studyChemotherapyCarcinomaMastectomyCommon Terminology Criteria for Adverse EventsBevacizumabAdjuvantLetrozoleLumpectomyMammographyDuctal carcinomaBreast-conserving surgeryNuclear medicineRadiation therapyBreast cancerMedicineGastroenterology
Publications 70
#1Céline Bourgier (French Institute of Health and Medical Research)H-Index: 27
#2Didier Cowen (AMU: Aix-Marseille University)H-Index: 1
Last. A. BenyoucefH-Index: 2
view all 29 authors...
PURPOSE To describe the quality assurance (QA) program and early toxicities in the phase III randomized trial BONBIS (NCT00907868) on the role of a localized radiation boost in ductal carcinoma in situ (DCIS). MATERIALS AND METHODS From November 2008 to July 2014, 2004 patients were randomized in arm A (only whole breast radiotherapy, WBRT) and arm B (WBRT + boost). The QA program involved 44 participant centers that performed the dummy run (DR). Compliance and uniformity of clinical target volu...
#1Jean-Michel Hannoun-Levi (University of Nice Sophia Antipolis)H-Index: 23
#2E. Van Limbergen (Katholieke Universiteit Leuven)H-Index: 15
Last. Vratislav StrnadH-Index: 30
view all 17 authors...
Introduction et but de l’etude Le second traitement conservateur emerge comme une option therapeutique en cas de second evenement tumoral du sein homolateral apres chirurgie conservatrice et irradiation du sein. Nous rapportons les resultats d’une comparaison entre second traitement conservateur et mastectomie de rattrapage en cas de second evenement tumoral du sein homolateral. Materiel et methodes Les resultats oncologiques apres le traitement d’un second evenement tumoral du sein homolateral ...
#1Céline BourgierH-Index: 27
#2C. LemanskiH-Index: 13
Last. D. AzriaH-Index: 19
view all 11 authors...
Resume La chirurgie conservatrice suivie d’une radiotherapie a legitime le developpement de l’association radiochirurgicale conservatrice comme le traitement de reference dans les lesions de petits volumes mais egalement dans les atteintes plus importantes grâce a la reduction volumique du traitement systemique neoadjuvant. Cependant, certaine toxicite cardiaque, pulmonaire, mais aussi cutanee a altere l’image et la qualite de vie a long terme d’un nombre limite de femmes traitees se considerant...
Background and Purpose: Recent phase 3 clinical trials have evaluated the addition of bevacizumab (B) to standard chemotherapy in the treatment of patients with non-metastatic breast cancer. But few data are available about the tolerance of B with locoregional radiation therapy (RT). The objective was to evaluate the 5 years late toxicities of the concurrent B and RT in non-metastatic breast cancer. Material and methods: This is a multicenter prospective study including non-metastatic breast can...
Abstract Purpose To determine the 3 years late toxicity among patients with non-metastatic breast cancer who received concurrent bevacizumab and locoregional radiotherapy. Material and methods This is a single-arm, multicentre, prospective study, of the toxicity of adjuvant concomitant association of bevacizumab and radiotherapy in patients with breast cancer. Toxicity was assessed by the Common Terminology Criteria for Adverse Events version 3.0 during the radiotherapy and follow-up clinics at ...
Purpose/Objectives The purpose of this study was to determine early and late toxicities among patients with non-metastatic breast cancer (BC) receiving concurrent bevacizumab (BV) and radiation therapy (RT). Materials/Methods Multicentre, prospective study, of the toxicity of adjuvant concomitant association of BV and RT in patients with non-metastatic BC enrolled in Phase 3 BEATRICE, BEVERLY and BETH trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse E...
#2P. FenogliettoH-Index: 5
Last. C. LemanskiH-Index: 13
view all 10 authors...
Purpose/Objective(s): We and others showed in retrospective and monocentric studies that radiation-induced CD8-lymphocyte apoptosis (RILA) can significantly predict differences in late toxicity between individuals and can be used as a rapid screening for potential hyper-reactive patients to radiation therapy (RT). We present here the clinical results of the prospective multicenter French trial (NCT00893035) evaluating the predictive role of RILA as a predictor of late effects after RT. Materials...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.